Phase II Two Stage Finding Run-in Study of SAR3419, An Anti-CD19 Antibody-Maytansine Conjugate, Administered as a Single Agent by Intravenous Infusion in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia.

Trial Profile

Phase II Two Stage Finding Run-in Study of SAR3419, An Anti-CD19 Antibody-Maytansine Conjugate, Administered as a Single Agent by Intravenous Infusion in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 19 May 2017

At a glance

  • Drugs Coltuximab ravtansine (Primary)
  • Indications Acute lymphoblastic leukaemia
  • Focus Therapeutic Use
  • Acronyms MYRALL
  • Sponsors Sanofi
  • Most Recent Events

    • 22 May 2014 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 18 Apr 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 25 Mar 2014 Planned End Date changed from 1 Nov 2015 to 1 May 2014 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top